Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 6934

1.

Relationship between glycemic control and diabetes-related hospital costs in patients with type 1 or type 2 diabetes mellitus.

Menzin J, Korn JR, Cohen J, Lobo F, Zhang B, Friedman M, Neumann PJ.

J Manag Care Pharm. 2010 May;16(4):264-75.

2.
3.

Economic burden in direct costs of concomitant chronic obstructive pulmonary disease and asthma in a Medicare Advantage population.

Blanchette CM, Gutierrez B, Ory C, Chang E, Akazawa M.

J Manag Care Pharm. 2008 Mar;14(2):176-85.

6.

It depends on what "mean" means: averaging versus event patterning in analyses of administrative claims data.

Fairman KA, Curtiss FR.

J Manag Care Pharm. 2010 May;16(4):288-91. No abstract available.

7.

Disease-related and all-cause health care costs of elderly patients with gout.

Wu EQ, Patel PA, Yu AP, Mody RR, Cahill KE, Tang J, Krishnan E.

J Manag Care Pharm. 2008 Mar;14(2):164-75.

8.

Direct all-cause health care costs associated with chronic kidney disease in patients with diabetes and hypertension: a managed care perspective.

Laliberté F, Bookhart BK, Vekeman F, Corral M, Duh MS, Bailey RA, Piech CT, Lefebvre P.

J Manag Care Pharm. 2009 May;15(4):312-22.

9.
10.
11.
12.

A comparison of insulin use, glycemic control, and health care costs with insulin detemir and insulin glargine in insulin-naive patients with type 2 diabetes.

Borah BJ, Darkow T, Bouchard J, Aagren M, Forma F, Alemayehu B.

Clin Ther. 2009 Mar;31(3):623-31. doi: 10.1016/j.clinthera.2009.03.005.

PMID:
19393853
14.

Associations between statin adherence level, health care costs, and utilization.

Zhao Y, Zabriski S, Bertram C.

J Manag Care Spec Pharm. 2014 Jul;20(7):703-13.

15.

The effect of a diabetes collaborative care management program on clinical and economic outcomes in patients with type 2 diabetes.

McAdam-Marx C, Dahal A, Jennings B, Singhal M, Gunning K.

J Manag Care Spec Pharm. 2015 Jun;21(6):452-68.

16.
17.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
18.
19.

Incremental cardiovascular costs and resource use associated with diabetes: an assessment of 29,863 patients in the US managed-care setting.

Straka RJ, Liu LZ, Girase PS, DeLorenzo A, Chapman RH.

Cardiovasc Diabetol. 2009 Sep 26;8:53. doi: 10.1186/1475-2840-8-53.

Supplemental Content

Support Center